Vince
Super Moderator
A new preclinical drug reported by James Bibb, Ph.D., and colleagues has the potential to combat depression, brain injury, and cognitive disorders. The drug, which is notable for being brain-permeable, works by inhibiting the kinase enzyme Cdk5.
Cdk5 is an important signaling regulator in brain neurons. Over three decades of research, it has been linked to neuropsychiatric and degenerative disorders such as Alzheimer’s
Alzheimes disease is a disease that attacks the brain, causing a decline in mental ability that worsens over time. It is the most common form of dementia and accounts for 60 to 80 percent of dementia cases. There is no current cure for Alzheimers disease, but there are medications that can help ease the symptoms. Alzheimer’s and Parkinson’s. Knocking out the enzyme in mice makes them more resilient to stress, improves cognition, protects neurons from stroke and brain trauma, and slows neurodegeneration.
scitechdaily-com.cdn.ampproject.org
Cdk5 is an important signaling regulator in brain neurons. Over three decades of research, it has been linked to neuropsychiatric and degenerative disorders such as Alzheimer’s
Alzheimes disease is a disease that attacks the brain, causing a decline in mental ability that worsens over time. It is the most common form of dementia and accounts for 60 to 80 percent of dementia cases. There is no current cure for Alzheimers disease, but there are medications that can help ease the symptoms. Alzheimer’s and Parkinson’s. Knocking out the enzyme in mice makes them more resilient to stress, improves cognition, protects neurons from stroke and brain trauma, and slows neurodegeneration.
New Drug Could Help Stop Depression, Anxiety, Brain Injury, and Cognitive Disorders
scitechdaily-com.cdn.ampproject.org
